* To replay the media content and watch again, please refresh your screen

In this first interactive patient case video from BREAST CANCER CONNECT expert Dr Elisa Agostinetto,  you will explore the complexities of a patient facing ER+/HER2- de novo metastatic breast cancer.

As you journey through the entire diagnostic and treatment process, you'll interact and engage with valuable information, challenging questions and clickable resources along the way.

In the second interactive patient case, Prof. Valentina Guarneri presents a patient with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • Assessing tumour characteristics, including prevalent mutations like ESR1 and PIK3CA, can significantly influence and guide treatment choices in patients with ER+/HER2- metastatic breast cancer

  • Liquid biopsy, specifically blood-based ctDNA analysis, is the preferred method for detecting ESR1 mutations due to its heightened sensitivity and the avoidance of repeat biopsies at metastatic sites

  • Elacestrant, as the first FDA-approved oral SERD (January 2023), offers a promising choice for select patients with ER+/HER2-  metastatic breast cancer harbouring an ESR1 mutation

  • Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Dr Elisa Agostinetto is a medical oncologist and leading researcher in the field of breast cancer. She received her medical degree in Italy, at University of Udine. She completed her training in medical oncology in Milan, Italy, and afterwards she moved to Brussels, Belgium, where she is currently pursuing an advanced research fellowship at Institut Jules Bordet - Université Libre de Bruxelles.

Dr Elisa Agostinetto has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Sandoz, AstraZeneca; support for conference attendence from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo, AstraZeneca and a research grant to her institution from Gilead.

Programme summary
  • clock Duration 15 MIN
  • clock Language(s) flag
Other episodes of this series
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 1

An interactive patient case video series from breast cancer specialists

Current Episode
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Experts
Prof. Amanda Tufman
Endorsed by
BRAF Bombers ICAN international cancer advocacy network Biomarker Collaborative
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar May 2025

This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
podcast Podcast
Oncology 
Understanding rare non-small cell lung cancer (NSCLC) alterations

Insights and support for patients

Experts
Dr Joshua Sabari, Debra Montague
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim
animated-video Animated Video
Oncology 
ADCs in HR+/HER2- metastatic breast cancer

Optimising treatment strategies and AE management

Experts
Dr Barbara Pistilli
Endorsed by
GRASP
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock MIN
  • calendar May 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
podcast Podcast

Episode

2

of 2

episode
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2

Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer

Experts
Dr Eric Singhi, Dr Isabel Preeshagul, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 18 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.